Tvardi Therapeutics has announced that the first patients have been dosed in each arm of its REVERT LIVER CANCER trial, which is evaluating TTI-101 as monotherapy and in combination with standard of care therapy for liver cancer. The trial is designed to evaluate TTI-101 across multiple lines of therapy and is currently enrolling HCC patients at top US cancer research institutes. Liver cancer is the sixth most commonly diagnosed cancer and the third most common cause of cancer death, with a 5-year survival rate of 18%. TTI-101's target, STAT3, plays a critical role in the pathogenesis of HCC by initiating tumorigenesis as well as promoting an immunosuppressive tumor microenvironment.
Tvardi Therapeutics, REVERT LIVER CANCER trial, TTI-101, STAT3 inhibitor, liver cancer Tvardi Therapeutics has begun Phase 2 clinical trials for hepatocellular carcinoma (HCC), metastatic breast cancer and idiopathic pulmonary fibrosis using its lead product TTI-101. The company’s REVERT LIVER CANCER trial will evaluate the safety and clinical activity of TTI-101 alone or combined with